This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Health Winners & Losers

Health stocks were stagnant at the start of the week as investors digested a regulatory letter affecting one stock and an upcoming advisory panel that will affect another.

The Nasdaq and Amex biotechnology indices were down less than half a percentage point Monday, while the Amex Pharmaceutical index lagged 0.7%, at 304.67.

Big Pharma stocks and components of the Amex index, GlaxoSmithKline (GSK - Get Report), Eli Lilly (LLY - Get Report) and Wyeth (WYE), were all down more than 1%.

On the advancing side, Discovery Labs (DSCO - Get Report) shares gained 31.7% to $1.91 Monday, recovering some of the ground lost Friday when news of regulatory delays hit the stock hard. The company said Monday it believes it will not need more clinical trials to gain Food and Drug Administration approval for its thrice-brushed off infant lung drug Surfaxin.

Meanwhile, investors weighed sentiment on Cephalon (CEPH), a day before an FDA advisory panel is set to meet to discuss expanded use of the company's pain drug Fentora. Lehman Brothers analyst Jim Birchenough lowered his price target for the stock to $88 from $93, ahead of the panel meeting.

Overall, Wall Street analysts were mixed about the mood and likely outcome of the panel, which will discuss ramifications of expanded approval of the pain drug, including a potential increase in its abuse. Shares edged down 46 cents, or 0.8%, to $60.12 Monday

In earnings, Albany Molecular (AMRI - Get Report) said first-quarter revenue increased 11% to $53.6 million. The research services firm reported adjusted profit of $4.7 million, or 15 cents a share, up from $3.1 million, or 10 cents a share, a year ago.

Analysts surveyed by Thomson Financial were looking for earnings of 3 cents a share on revenue of $47.6 million. Shares added $1.83, or 16%, to $13.30.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ARTC $48.60 0.08%
AMRI $20.26 -1.60%
DSCO $0.41 -2.80%
GSK $41.03 -0.53%
LLY $82.25 -1.10%

Markets

Chart of I:DJI
DOW 16,531.17 -111.84 -0.67%
S&P 500 1,973.98 -14.89 -0.75%
NASDAQ 4,791.0530 -37.2720 -0.77%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs